MCS110 With BRAF/MEK Inhibition in Patients With Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03455764

Recruitment Status : Active, not recruiting

First Posted : March 7, 2018

Last Update Posted : December 16, 2022

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborator:

Novartis

Information provided by (Responsible Party):

Elizabeth Buchbinder, MD, Dana-Farber Cancer Institute

Results Submitted - Quality Control (QC) Review Has Not Concluded

Results information for an applicable clinical trial (ACT) is posted within 30 days of submission even if the submission has not completed the ClinicalTrials.gov Results Quality Control (QC) review process. Results information is submitted to ClinicalTrials.gov by the sponsor or investigator, and National Library of Medicine (NLM) staff assess for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.

All versions of ACT results information submissions that have not completed the QC review process are posted on ClinicalTrials.gov (since January 2020). After the QC review process is completed, the results information is posted without QC review comments and previous versions are archived.

Recruitment Status :	Active, not recruiting
Estimated Primary Completion Date :	September 30, 2024
Estimated Study Completion Date :	September 30, 2025

Submission Cycle	Results Submitted to ClinicalTrials.gov	Results Returned after Quality Control Review
1	November 1, 2023	November 21, 2023 Submission with QC Comments
2	April 24, 2024

To Top